These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

83 related items for PubMed ID: 28185938

  • 1. Folate-targeted nanoparticle delivery of androgen receptor shRNA enhances the sensitivity of hormone-independent prostate cancer to radiotherapy.
    Zhang X, Liu N, Shao Z, Qiu H, Yao H, Ji J, Wang J, Lu W, Chen RC, Zhang L.
    Nanomedicine; 2017 May; 13(4):1309-1321. PubMed ID: 28185938
    [Abstract] [Full Text] [Related]

  • 2. Nanoparticle formulation of small DNA molecules, Dbait, improves the sensitivity of hormone-independent prostate cancer to radiotherapy.
    Yao H, Qiu H, Shao Z, Wang G, Wang J, Yao Y, Xin Y, Zhou M, Wang AZ, Zhang L.
    Nanomedicine; 2016 Nov; 12(8):2261-2271. PubMed ID: 27389144
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Cyclin D1 silencing suppresses tumorigenicity, impairs DNA double strand break repair and thus radiosensitizes androgen-independent prostate cancer cells to DNA damage.
    Marampon F, Gravina G, Ju X, Vetuschi A, Sferra R, Casimiro M, Pompili S, Festuccia C, Colapietro A, Gaudio E, Di Cesare E, Tombolini V, Pestell RG.
    Oncotarget; 2016 Feb 02; 7(5):5383-400. PubMed ID: 26689991
    [Abstract] [Full Text] [Related]

  • 5. Preclinical study using androgen receptor (AR) degradation enhancer to increase radiotherapy efficacy via targeting radiation-increased AR to better suppress prostate cancer progression.
    Chou FJ, Chen Y, Chen D, Niu Y, Li G, Keng P, Yeh S, Chang C.
    EBioMedicine; 2019 Feb 02; 40():504-516. PubMed ID: 30692044
    [Abstract] [Full Text] [Related]

  • 6. Prostate-targeted biodegradable nanoparticles loaded with androgen receptor silencing constructs eradicate xenograft tumors in mice.
    Yang J, Xie SX, Huang Y, Ling M, Liu J, Ran Y, Wang Y, Thrasher JB, Berkland C, Li B.
    Nanomedicine (Lond); 2012 Sep 02; 7(9):1297-309. PubMed ID: 22583574
    [Abstract] [Full Text] [Related]

  • 7. [Androgen receptor silencing by shRNA inhibits human prostate cancer xenograft growth in nude mice].
    Wang T, Xu QQ, Huang XB, Wang XF.
    Beijing Da Xue Xue Bao Yi Xue Ban; 2013 Aug 18; 45(4):527-31. PubMed ID: 23939155
    [Abstract] [Full Text] [Related]

  • 8. Lipid nanoparticle siRNA systems for silencing the androgen receptor in human prostate cancer in vivo.
    Lee JB, Zhang K, Tam YY, Tam YK, Belliveau NM, Sung VY, Lin PJ, LeBlanc E, Ciufolini MA, Rennie PS, Cullis PR.
    Int J Cancer; 2012 Sep 01; 131(5):E781-90. PubMed ID: 22095615
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Artesunate Suppresses the Growth of Prostatic Cancer Cells through Inhibiting Androgen Receptor.
    Wang Z, Wang C, Wu Z, Xue J, Shen B, Zuo W, Wang Z, Wang SL.
    Biol Pharm Bull; 2017 Sep 01; 40(4):479-485. PubMed ID: 28381803
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Combination of carmustine and selenite effectively inhibits tumor growth by targeting androgen receptor, androgen receptor-variants, and Akt in preclinical models: New hope for patients with castration resistant prostate cancer.
    Thamilselvan V, Menon M, Thamilselvan S.
    Int J Cancer; 2016 Oct 01; 139(7):1632-47. PubMed ID: 27198552
    [Abstract] [Full Text] [Related]

  • 14. Targeting androgen receptor versus targeting androgens to suppress castration resistant prostate cancer.
    Guo C, Yeh S, Niu Y, Li G, Zheng J, Li L, Chang C.
    Cancer Lett; 2017 Jul 01; 397():133-143. PubMed ID: 28323036
    [Abstract] [Full Text] [Related]

  • 15. Identification of an anabolic selective androgen receptor modulator that actively induces death of androgen-independent prostate cancer cells.
    Schmidt A, Meissner RS, Gentile MA, Chisamore MJ, Opas EE, Scafonas A, Cusick TE, Gambone C, Pennypacker B, Hodor P, Perkins JJ, Bai C, Ferraro D, Bettoun DJ, Wilkinson HA, Alves SE, Flores O, Ray WJ.
    J Steroid Biochem Mol Biol; 2014 Sep 01; 143():29-39. PubMed ID: 24565564
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Antiandrogenic effects of novel androgen synthesis inhibitors on hormone-dependent prostate cancer.
    Long BJ, Grigoryev DN, Nnane IP, Liu Y, Ling YZ, Brodie AM.
    Cancer Res; 2000 Dec 01; 60(23):6630-40. PubMed ID: 11118046
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. High Efficacy of Combination Therapy Using PI3K/AKT Inhibitors with Androgen Deprivation in Prostate Cancer Preclinical Models.
    Marques RB, Aghai A, de Ridder CMA, Stuurman D, Hoeben S, Boer A, Ellston RP, Barry ST, Davies BR, Trapman J, van Weerden WM.
    Eur Urol; 2015 Jun 01; 67(6):1177-1185. PubMed ID: 25220373
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.